Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

Model scores of the 29,894 trials active now.

Model score 5% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (776 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-10-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Primary purpose: other (lowers risk) · Design
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: safety tolerabilityascendingtolerability anddosesthe safety
  Phrases that lowered it: healthyvolunteersmmhgsinglekg
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Drug's FAERS reports with a death: 31.7% (raises risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Number of arms: 6 (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: double (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 97.1% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 21653 (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 55 (lowers risk) · Who can join
• Responsible party: sponsor (lowers risk) · Design
• Sponsor's past trials: 0 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Single and Multiple Ascending Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of KP-1199 NCT03880487 · started 2019 · scored riskier than 4% of active trials terminated
• To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104 NCT05490017 · started 2020 · scored riskier than 7% of active trials completed
• A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of PMK-S005 After Oral Administration in Healthy Male Volunteers NCT01762397 · started 2012 · scored riskier than 2% of active trials completed
• Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994 NCT03395249 · started 2017 · scored riskier than 5% of active trials completed
• A Randomized Phase 1 of of MZE001 in Healthy Volunteers NCT05249621 · started 2022 · scored riskier than 6% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.